AIDP analysis
Automated Imaging Differentiation of Parkinsonism
Differentiate between Parkinson’s Disease (PD), Multiple System Atrophy (MSAp), and Progressive Supranuclear Palsy (PSP) with over 96% accuracy using our FDA classified Parkinsonian syndrome diagnostic aid. Built by experts. Backed by science. Designed for improving clinical outcomes.
How does AIDP work?
AIDP analyzes a diffusion MRI scan and provides a classification report that differentiates between three major Parkinsonian variants.
Free-Water Imaging Analysis
AIDP analysis is based on Free-Water Imaging (FWI), which is a powerful enhancement to diffusion MRI scan processing techniques that separates true brain tissue signal from excess extracellular water.
Sharper microstructural insight
Measures severity, rate, and state of degeneration.
Earlier disease detection
Detects subtle microstructural changes between closer timepoints, beyond what volumetric imaging sees.
Improved differentiation across Parkinsonism subtypes
Improves outcomes for healthcare and clinical trials.
96%
Up to 96% accuracy
21 sites
involved in most recent clinical trial
15+
Years of data collected
1000+
Unique datasets analyzed
Exclusive, FDA Classified, Patented Technology
neuropacs™ leverages proprietary, patent-protected and FDA classified technology.
- Classified by FDA as the first Parkinsonian syndrome diagnostic aid DEN240071.
-
AI-driven diagnostics trained on
harmonized multi-site data
- Exclusive Patent: US 10,758,170 for Parkinsonism
- Free-Water Imaging (FWI): A powerful diffusion MRI method that enhances early disease detection
Comprehensive Toolset
Delivered via secure cloud-based workflow
Unmatched Accuracy
Up to 96% precision in distinguishing PD from MSAp and PSP
Whether supporting clinical decision-making or powering trial success, neuropacs™ provides exclusive methodologies, actionable insights, and a seamless integration into existing imaging workflows.
neuropacsTM agent DEMO
This video explains how our diagnostic software can be seamlessly integrated with your existing PACS system using our state-of-the-art secure and scalable cloud solution.
FAQs
Frequently asked questions
What MRI sequence can AIDP analyze?
Can I integrate AIDP into my existing PACS environment?
Ready to improve your outcomes using our precision AI platform?
Our dedicated team can help you determine which neuropacs™ solution best fits your clinical or research needs.
Important Safety Information: AIDP is intended to provide supplemental information and is not a standalone diagnostic device. Results should be interpreted in conjunction with clinical evaluation and other diagnostic testing. This device does not rule out other potential causes of Parkinsonism symptoms or signs and is intended to be used after all other potential causes of Parkinsonism symptoms (such as dementia with Lewy bodies, vascular Parkinsonism, drug-induced Parkinsonism, and corticobasal degeneration/syndrome) have been ruled out by trained clinicians on the basis of clinical, neurological, and other laboratory tests. Patient management decisions should not be based solely on AIDP output.